Enzon Pharmaceuticals Inc  

(Public, OTCMKTS:ENZN)   Watch this stock  
Find more results for NASDAQ:ENZN
-0.001 (-0.25%)
Jul 25 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.39 - 0.39
52 week 0.38 - 1.56
Open 0.39
Vol / Avg. 58,220.00/118,367.00
Mkt cap 17.33M
P/E 0.55
Div/yield 0.25
EPS 0.72
Shares 44.21M
Beta 0.86
Inst. own 39%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 46.45% 123.95%
Operating margin 77.92% 61.87%
EBITD margin - 87.68%
Return on average assets 28.46% 74.70%
Return on average equity 32.28% 90.74%
Employees 1 -
CDP Score - -


20 Commerce Drive, Suite 135
United States - Map
+1-732-9804500 (Phone)
+1-302-6555049 (Fax)

Website links


Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.

Officers and directors

Jonathan N. Christodoro Chairman of the Board
Age: 40
Andrew D. Rackear J.D. Chief Executive Officer, Secretary
Age: 60
Richard L. Feinstein Chief Financial Officer, Vice President - Finance
Age: 71
Odysseas D. Kostas M.D. Director
Age: 40
Jennifer I. McNealey Director
Age: 41